February 27, 2020

Newsmakers: Vigene Biosciences Dr. Jeffrey Hung, C...

Contract Pharma talks with Dr. Jeffrey Hung, CCO of Vigene, about the manufacturing challenges of cell and gene therapies.
February 27, 2020

Biosciences Facility Opens in Rockville, Striding ...

MyMCMedia reported on the grand opening of Vigene Biosciences’s new 51,000-square-feet GMP viral vector manufacture facility. The $20 million, state-of-the-art […]
February 27, 2020

New bioscience company makes way to Montgomery Cou...

I270 News (WDVM-TV) reported on the grand opening of Vigene Biosciences’s 51,000 square-feet new GMP manufacture facility. Vigene Biosciences’ mission […]
February 27, 2020

Rockville biotech opens new HQ as it goes on hirin...

Washington Business Journal reported on the grand opening of Vigene Biosciences’s Rockville 51,000 square-feet new GMP manufacture facility to meet […]
February 27, 2020

Vigene Biosciences Awarded Patent for improvements...

ROCKVILLE, Md. – February 24, 2020 – Vigene Biosciences, Inc. (Vigene), a leading biotechnology company for viral vector production and […]
February 27, 2020

Vigene and ASC Therapeutics Announce Long-Term Str...

ROCKVILLE, Md. Vigene Biosciences, Inc. (Vigene), a leading biotechnology company for viral vector production and development for cell and gene […]
February 27, 2020

Vigene Biosciences Opens State-Of-The-Art Headquar...

ROCKVILLE, MD – January 29, 2020 – Vigene Biosciences, Inc. (Vigene), a pioneer in the viral gene delivery space, unveils […]
February 27, 2020

Vigene Biosciences Secures Institutional Investmen...

Rockville, MD. – April 29, 2019 – Vigene Biosciences, Inc (“Vigene”) a leading provider of viral vector products and services […]
March 29, 2019

Upcoming Events

ISBioTech Spring Meeting - March 23-25
Norfolk, VA
Gene Therapy for Rare Disorders - March 30-April 2
Boston, MA
ASGCT, - May 12-15
Boston, MA
March 29, 2019

Product Launches

We now offer the newest iterations of the GCaMP family of calcium biosensors: jGCaMP7! Available as 4 variants.